Skip to main content

Table 4 Univariate Cox regression analysis for disease free survival and overall survival

From: Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up

  DFS OS
  Event HR 95% CI P-value Event HR 95% CI P-value
Gender         
 Male (n = 101) 41 1.00    33 1.00   
 Female (n = 27) 8 0.69 0.32-1.47 0.33 3 0.35 0.11-1.14 0.08
WHO Classification         
 Type I (n = 6) 3 1.00    1 1.00   
 Type II (n = 43) 17 0.63 0.18-2.14 0.46 12 1.59 0.21-12.22 0.66
 Type III (n = 79) 29 0.61 0.19-2.02 0.42 23 1.68 0.23-12.47 0.61
cT         
 T1-2 (n = 75) 21 1.00    13 1.00   
 T3-4 (n = 53) 28 2.19 1.24-3.85 0.007 23 2.9 1.47-5.73 0.002
cN         
 N0-1 (n = 34) 11 1.00    10 1.00   
 N2-3 (n = 94) 38 1.38 0.70-2.70 0.35 26 1.06 0.49-2.13 0.95
Stage         
 IIB/III (n = 83) 23 1.00    15 1.00   
 IVA/IVB (n = 45) 26 2.70 1.54-4.74 0.0006 21 3.00 1.54-5.83 0.001
Treatment         
 CCRT group (n = 90) 31 1.00    25 1.00   
 NACT group (n = 38) 18 1.38 0.77-2.46 0.28 11 1.04 0.51-2.12 0.91
  1. DFS, disease free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.